Clinical Trial Update: A Biomarker Study to Predict Treatment Outcomes of Enfortumab Vedotin in Advanced Urothelial Carcinoma

View source ↗

Summary

A biomarker study to predict treatment outcomes of enfortumab vedotin in advanced urothelial carcinoma; the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Enfortumab Vedotin (enfortumab vedotin)

Snippet

Sponsor: National Taiwan University Clinical Trial Center | Conditions: Advanced Urothelial Carcinoma | Status: ACTIVE_NOT_RECRUITING